CD73 (5
0 -nucleotidase) expression has no prognostic value in children with acute lymphoblastic leukemia Ecto-5 0 -nucleotidase, also known as CD73, is a glycosyl phosphatidylinositol-linked enzyme on the cell surface of a variety of cell types, 1,2 which catalyzes the dephosphorylation of AMP and other nucleoside monophosphates.
1 CD73, originally defined as a lymphocyte differentiation antigen, is thought to function as an adhesion molecule necessary for lymphocyte binding to endothelium 3 and a co-signaling molecule on T lymphocytes when ligated by antibodies.
1
Two earlier studies showed the expression of CD73 on childhood acute lymphoblastic leukemia (ALL) cells.
4, 5 The expression of CD73 in common ALL (C-ALL) and pre-B-ALL varied from absent to very high and was low or absent in T-lineage ALL, pro-B-ALL and mature B-ALL. Both our earlier studies suggested that a high expression of CD73 was related to a poor prognosis in pre-B-ALL and C-ALL. 4, 5 However, both studies were retrospective and included only small series of patients. Therefore, we evaluated prospectively whether CD73 predicts outcome in a recent treatment protocol for childhood ALL. The study was approved by the Institutional Review Board.
CD73 was measured on 411 bone marrow cells of children with ALL aged 1-18 years who were included in the Dutch Childhood Oncology Group (DCOG) (formerly the Dutch Childhood Leukemia Study Group) ALL-9 protocol and diagnosed between 22 May 1997 and 29 Apr 2001. Mononuclear cells were isolated on a Ficoll-isopaque gradient and used after cryopreservation as described before. 6 Immunofluorescence staining was performed with MoAb CD73 FITC conjugated. The CD73 antibody 7G2 was available, thanks to Linda F Thompson (Oklahoma, USA). 7 After rinsing twice, FITCconjugated rabbit antimouse immunoglobulin G with phosphate-buffered saline (PBS) þ 1% bovine serum albumin (BSA) was added for 30 min. Cells were rinsed twice and resuspended in 0.3 ml PBS/BSA/sodium azide. Fluorescence was measured with a FACScan (Becton Dickinson, San Jose, CA, USA).
All results were updated until August 2008. The primary end point was event-free survival (EFS). EFS was defined as the time from diagnosis to relapse, death in remission or the occurrence of a second tumor. Patients who did not achieve complete remission, either because of death in induction or because of resistant disease at the end of induction, were considered as treatment failures on day 0.
The immunophenotypic subclasses pre-B-ALL and C-ALL showed no significant difference in the expression of CD73 (median percentage of cells with CD73 expression, 32% and 37%, respectively, P ¼ 0.554). T-ALL showed a significant lower expression of CD73 compared with pre-B-ALL/C-ALL (P ¼ 0.000; Table 1 ). Four out of the five pro-B-ALL cases had a very low expression of CD73 and one had a very high expression (Figure 1) .
Further analysis was done only for the 338 patients with pre-B-ALL and C-ALL. Males and females showed no significant difference in the expression of CD73 (P ¼ 0.703; Table 1 ). Patients younger than 10 years of age showed no significant difference in the expression of CD73 compared with patients older than 10 years of age. Patients with a white-blood-cell count o20/ml did show a slight but significant lower expression of CD73 compared with patients with a white-blood-cell count 420/ml (P ¼ 0.050). Patients with central nervous system (CNS) involvement did not show a significant different expression of CD73 compared with patients without CNS involvement (P ¼ 0.487). Furthermore, patients with the different genetic abnormalities ETV6-RUNX1 t(12;21), BCR-ABL1 t(9;22), mixed lineage leukemia (MLL) rearrangement, t (1;19), hyperdiploid (50-60) or other cytogenetic mutations did not show different expressions of CD73 compared with cases with normal cytogenetics.
Pre-B-ALL/C-ALL patients were divided in two groups with low and high CD73 expression based upon the median value of 35% CD73-positive cells. The 8-year EFS did not differ significantly between patients with low CD73 expression (EFS 79.9%) and patients with high CD73 expression (EFS 81.6%, P ¼ 0.639; Figure 2 ). When other cutoffs were chosen for CD73 (p25 or p75), there was no significant difference in the 8-year EFS either. Moreover, when only cases with 80% blasts or more were selected with a cutoff of CD73 of 35%, no significant difference in the 8-year EFS was found (P ¼ 0.952).
This study confirms our earlier findings that T-ALL and pro-B-ALL had low or absent CD73 expression and CD73 expression varied highly within C-ALL/Pre-B-ALL. 4, 5 Our earlier small studies suggested that CD73 had prognostic value in children with C-ALL/pre-B-ALL. 4, 5 This was thought to be due to its effect on 6-mercatopurine sensitivity. 8 However, the present much larger and prospective study shows that the long-term EFS appeared not to be dependent on the level of CD73 expression. In conclusion, CD73 does not influence the prognosis of children with ALL on a modern treatment protocol. Abbreviations: ALL, acute lymphoblastic leukemia; C-ALL, common ALL; CNS, central nervous system; MLL, mixed lineage leukemia. Letters to the Editor
